Enroll Now
You Must LOG IN to Enroll
Publication Date: 17 March 2026
The Case for Universal Leukoreduction of Blood Transfusions
Continuing Education Credits: 0.5 hours
Course Description
This lecture by Dr. Neil Blumberg, MD demonstrates that leukoreduction of blood transfusions has been shown in randomized trials or high-quality observational trials to reduce immunologic complications such as febrile/rigor transfusion reactions, post-operative infections, cardiac surgery mortality, platelet transfusion refractoriness, cytomegalovirus transmission, and complications of the premature newborn such as retinopathy. Observational data also preliminarily suggest that the occurrence of TRALI (acute lung injury) and TACO (congestive heart failure), graft versus host disease, red cell alloimmunization, and post-transfusion purpura may be mitigated. Universal leukoreduction was introduced worldwide, except in the USA, about the years 1998-2000. Data suggest that while blood transfusion service costs increase, there are substantial overall savings to health care systems through decreased complications and length of stay.
Course Objectives
- Employ leukoreduction of cellular products such as platelets and red cells into all transfusions in your institution
- When assessing risk:benefit, include nosocomial infection, alloimmunization to red cell alloantigens, and mortality into your determinations
- When assessing cost:benefit, include reductions in length of stay and resource utilization with universal leukoreduction into your calculations
Run Time: 18:31
Course Instructor Bio(s)
Neil Blumberg, MD
Professor of Pathology and Laboratory Medicine and Transfusion Medicine/Blood Bank
University of Rochester
Rochester, New York, USA
Dr. Neil Blumberg is a Professor at the University of Rochester, NY, and served as Director of the Transfusion Medicine Division and Blood Bank of an 880‑bed university hospital from 1980 to 2025. He holds BS and MD degrees from Yale University in New Haven, CT, and completed residency training in laboratory medicine, hematology, and blood banking at Yale New Haven Hospital.
Dr. Blumberg has a longstanding interest in transfusion immunology, with significant contributions to understanding the immunologic effects of transfusion, particularly the phenomenon of transfusion‑related immunomodulation. Clinically, his focus includes the diagnosis and management of immune-mediated disorders such as autoimmune hemolytic anemia and autoimmune thrombocytopenia, as well as supportive care for patients undergoing stem cell or solid organ transplantation. He also emphasizes the use of simple, cost‑effective methods to reduce transfusion‑related complications, including leukoreduction, autologous transfusion, and removal of stored supernatant through washing.
Together with Dr. Joanna M. Heal, MRCP, Dr. Blumberg’s group has defined the benefits of ABO‑identical transfusion through innovative laboratory and clinical research. Their work has also highlighted the harmful effects of transfusing ABO‑incompatible soluble antigens and antibodies. The combined use of leukoreduction, washing, and ABO‑identical transfusion has reduced five‑year mortality in younger patients with leukemia in their setting from 50% to 20%. These strategies have also decreased the incidence of platelet refractoriness to nearly zero by avoiding exposure to incompatible antigens and antibodies. Overall, these approaches reduce inflammation, organ failure, transfusion reactions of all types, TRALI, TACO, and alloimmunization to red blood cell antigens. In addition, minimizing unnecessary transfusions further mitigates these adverse outcomes, including the risk of thrombosis.
